




RealRate

PHARMACEUTICAL 2022

Xeris Biopharma Holdings Inc. Rank 273 of 475



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



RealRate

PHARMACEUTICAL 2022

Xeris Biopharma Holdings Inc. Rank 273 of 475



The relative strengths and weaknesses of Xeris Biopharma Holdings Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Xeris Biopharma Holdings Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 127% points. The greatest weakness of Xeris Biopharma Holdings Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 101% points.

The company's Economic Capital Ratio, given in the ranking table, is -153%, being 123% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	142,596
Cost of Goods Sold	0
Intangible Assets	154,309
Liabilities, Current	79,040
Liabilities, Non-Current	1,676
Other Assets	829
Other Compr. Net Income	-37
Other Expenses	13,868
Other Liabilities	128,414
Other Net Income	-7,569
Property and Equipment	6,627
Research and Development	25,160
Revenues	49,590
Selling, General and Administrative Expense	125,718

Output Variable	Value in 1000 USD
Assets	304,361
Liabilities	209,130
Expenses	164,746
Stockholders Equity	95,231
Net Income	-122,725
Comprehensive Net Income	-122,744
Economic Capital Ratio	-153%



RealRate